Special Issue

Personalized Medicine: Pharmacokinetics

Message from the Guest Editor

The present issue could address:

- Recent updates in genetic polymorphisms of metabolic enzymes, transporters and their implication in different medical fields (oncology, psychiatry, cardiovascular, etc.)
- Genetic polymorphisms affecting pharmacodynamics of drugs in oncology
- Pharmacogenetics and pharmacogenomics of tyrosine kinase inhibitors
- Pharmacogenetics and pharmacogenomics of anticoagulant and antiplatelet drugs
- Better characterization of drugs metabolism and transport during the development and use of physiologically based pharmacokinetics (PBPK) for optimal use in clinical settings

Guest Editor

Prof. Dr. Youssef Daali

Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals, 1205 Geneva, Switzerland

Deadline for manuscript submissions

closed (20 July 2021)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/56188

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

